Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare

Published: Thursday, October 25, 2012
Last Updated: Wednesday, October 24, 2012
Bookmark and Share
Strategic alliance for the production of antibody drug conjugates.

Fujifilm Diosynth Biotechnologies has announced that it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

The deal will allow customers to benefit from the experience and assets of both organizations, while simplifying the supply chain and vendor management relationships, leading to shorter time to clinic.

Fujifilm Diosynth Biotechnologies is one of the world's leading providers of contract development and manufacturing services for biopharmaceuticals, whilst Piramal is a world leader in antibody drug conjugation.

The combined experience covers work on more than 150 biopharmaceuticals and over 300 batches of ADCs spanning over more than 30 different NCEs, including the world's only FDA-approved ADC.

For Fujifilm Diosynth Biotechnologies, this is part of an ongoing programme to expand its offering in mammalian-based biopharmaceuticals.

The company recently announced an expansion of its cGMP manufacturing facilities at both its RTP, USA and Billingham, UK sites.

Stephen Taylor, Commercial Vice President of Fujifilm Diosynth Biotechnologies said "This strategic alliance with Piramal is an important step for us in bringing a new, high-technology offering to the market place. Our customers will benefit from high quality, consistent material, rapid service and shorter logistical chains, saving time on the critical path of drug development. Piramal is a recognized world-leader in this area and we are delighted to be partnering with them".

Aidan Walker, President Formulations Services, Piramal said "We are delighted to combine with Fujifilm Diosynth Biotechnologies to offer a seamless service to customers for the production of antibody conjugates. Fujifilm Diosynth Biotechnologies has a long track-record in delivering successful biologics programmes, and this alliance will combine strengths from both companies for the benefit of our customers, and ultimately patients".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FUJIFILM Completes Acquisition of Kalon Biotherapeutics
Acquisition enhances Texas’ growing reputation as a global biotechnology leader.
Friday, December 19, 2014
Fujifilm Diosynth Biotechnologies Expands Cell Culture Manufacturing Capacity
The company expands capabilities with the addition of two new 2,000l single-use bioreactors.
Tuesday, August 19, 2014
Fujifilm Diosynth Biotechnologies Continues Expansion of R&D Facilities
Company invests more than US$5.6M in new laboratories and equipment.
Wednesday, June 25, 2014
Fujifilm Diosynth Biotechnologies’ UK Site Receives Renewed Manufacturing Licence
Licence authorizes commercial manufacturing at the company’s Billingham, UK site.
Thursday, October 10, 2013
Fujifilm Diosynth Biotechnologies Manufactures a New Licensed Biopharmaceutical
ThromboGenics' has received FDA approval for the launch of JETREA® in the USA.
Thursday, November 15, 2012
Fujifilm Diosynth Expands R&D Capabilities at its Billingham, UK Site
Company has completed the first phase of a $4.5m investment in new equipment and laboratories.
Friday, April 06, 2012
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!